Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer

Oncology Reports

Volumn 21, Issue 1, 2009, Pages 165-171

  Tiovonen, Raine ^a   Suominen, Elina ^a   Grenman, Reidar ^a   Savontaus, Mikko ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Adenovirus; Head and neck cancer; Telomerase

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; E1A PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; CAR RECEPTOR; MEMBRANE COFACTOR PROTEIN; ONCOLYTIC VIRUS; TELOMERASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HEAD AND NECK CANCER; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE; TUMOR REGRESSION; ADENOVIRUS; ANIMAL; BIOSYNTHESIS; FLOW CYTOMETRY; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK TUMOR; HUMAN; HYBRID CELL; METABOLISM; METHODOLOGY; MOUSE; SQUAMOUS CELL CARCINOMA; VIROLOGY;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIGENS, CD46; CARCINOMA, SQUAMOUS CELL; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; HYBRID CELLS; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECEPTORS, VIRUS; TELOMERASE; TRANSDUCTION, GENETIC; TRANSFECTION; VIRAL PROTEINS;

EID: 61449442370     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000204     Document Type: Article

References (38)

1. Bergelson JM, Cunningham JA, Droguett G, et al: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323, 1997.
2. Tomko RP, Xu R and Philipson L: HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356, 1997.
3. Roelvink PW, Lizonova A, Lee JG, et al: The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 72: 7909-7915, 1998.
4. Wickham TJ, Mathias P, Cheresh DA and Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319, 1993.
5. Li D, Duan L, Freimuth P and O'Malley BW Jr: Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 5: 4175-4181, 1999.
6. Hemmi S, Geertsen R, Mezzacasa A, Peter I and Dummer R: The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 9: 2363-2373, 1998.
7. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM and Kovesdi I: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 70: 6831-6838, 1996.
8. Nettelbeck DM, Miller DW, Jerome V, et al: Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 3: 882-891, 2001.
9. Kasono K, Blackwell JL, Douglas JT, et al: Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res 5: 2571-2579, 1999.
10. Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I and Wickham TJ: Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 75: 11284-11291, 2001.
11. Gaggar A, Shayakhmetov DM and Lieber A: CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412, 2003.
12. Seya T, Hirano A, Matsumoto M, Nomura M and Ueda S: Human membrane cofactor protein (MCP, CD46): multiple isoforms and functions. Int J Biochem Cell Biol 31: 1255-1260, 1999.
13. Shayakhmetov DM, Li ZY, Ni S and Lieber A: Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 62: 1063-1068, 2002.
14. Segerman A, Mei YF and Wadell G: Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines. J Virol 74: 1457-1467, 2000.
15. Sova P, Ren XW, Ni S, Bernt KM, Mi J, Kiviat N and Lieber A: A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 9: 496-509, 2004.
16. Shinozaki K, Suominen E, Carrick F, et al: Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. Gene Ther 13: 52-59, 2006.
17. Suominen E, Toivonen R, Grenman R and Savontaus M: Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus. J Gene Med 8: 1223-1231, 2006.
18. Haviv YS and Curiel DT: Engineering regulatory elements for conditionally-replicative adeno-viruses. Curr Gene Ther 3: 357-385, 2003.
19. Ito H, Kyo S, Kanaya T, Takakura M, Koshida K, Namiki M and Inoue M: Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 4: 2807-2810, 1998.
20. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M and Inoue M: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59: 551-557, 1999.
21. Shay JW, Zou Y, Hiyama E and Wright WE: Telomerase and cancer. Hum Mol Genet 10: 677-685, 2001.
22. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV and Woo SL: Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 10: 1241-1247, 2003.
23. Kawashima T, Kagawa S, Kobayashi N, et al: Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 10: 285-292, 2004.
24. Kim E, Kim JH, Shin HY, et al: Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 14: 1415-1428, 2003.
25. Zou W, Luo C, Zhang Z, et al: A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 23: 457-464, 2004.
26. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
27. Fuller CD, Wang SJ, Thomas CR Jr, Hoffman HT, Weber RS and Rosenthal DI: Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998. Cancer 109: 1331-1343, 2007.
28. Khuri FR, Nemunaitis J, Ganly I, et al: a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885, 2000.
29. Grenman SE, Van Dyke DL, Worsham MJ, et al: Phenotypic characterization, karyotype analysis and in vitro tamoxifen sensitivity of new ER-negative vulvar carcinoma cell lines, UM-SCV-1A and UM-SCV-1B. Int J Cancer 45: 920-927, 1990.
30. Bautista DS, Hitt M, McGrory J and Graham FL: Isolation and characterization of insertion mutants in E1A of adenovirus type 5. Virology 182: 578-596, 1991.
31. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G and Lieber A: Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 74: 2567-2583, 2000.
32. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
33. Goebel EA, Davidson BL, Zabner J, Graham SM and Kern JA: Adenovirus-mediated gene therapy for head and neck squamous cell carcinomas. Ann Otol Rhinol Laryngol 105: 562-567, 1996.
34. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M and Cabrini G: Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 75: 8772-8780, 2001.
35. Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP and Lieber A: Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum. Gene Ther 16: 664-677, 2005.
36. Rocconi RP, Zhu ZB, Stoff-Khalili M, et al: Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gynecol Oncol 105: 113-121, 2007.
37. Irving J, Wang Z, Powell S, et al: Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 11: 174-185, 2004.
38. Bilsland AE, Merron A, Vassaux G and Keith WN: Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res 67: 1299-1307, 2007.